Join today and have your say! It’s FREE!
We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}

Join today with :

or

By providing my email, I consent to receiving investment related electronic messages from Stockhouse.
Sign in with existing account
Please Try Again
{{ error }}

Sign In With :

or

Password Hint : {{passwordHint}}
Forgot Password?
Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Positive Results for Nash’s Crohn’s Lead Compound Study

Stockhouse Editorial
0 Comments| December 3, 2018


Nash Pharmaceuticals, a wholly-owned subsidiary of Breathtec Biomedical Inc. (CSE: BTHOTCQB: BTHCDForum), announced on Monday that its lead compound for the treatment of ulcerative colitis (UC), performed as good as, and in some measurements, better than, the current global standard of care treatment for inflammatory bowel disease (IBD). This means that a new potential treatment for Crohn’s disease could lead to an orphan drug designation, which could help expedite its availability to patients.

For more information, click here.

The Company recently made news when it stated that that one of its lead compounds for chronic kidney disease (“CKD”) NP-135 showed positive results in a recently completed study investigating its therapeutic effects in a unilateral ureteral obstruction mouse model of kidney fibrosis.

 
FULL DISCLOSURE: Breathtec Biomedical Inc. is a paid client of Stockhouse Publishing.



Interested in these industries and sectors?

Receive investor kits and email updates from Stockhouse and directly from these companies.

Healthcare
Metals & Mining
Technology
Industrials

Interested in these industries and sectors?

You are already a member! Please enter your password to sign in.

Comments

No comments yet. Be first to comment!

Leave a Comment

You must be logged in to access this feature.


×

StockTalk
Get our FREE StockTalk Investor Guides by sector as they are released!

Stay on top of sector specific news, get industry leaders insights and our best content, delivered to your email.

You are already a member! Please enter your password to sign in.